CDKN2A and head and neck squamous cell carcinoma: A 2017 meta-analysis of both OPSCC and HNSCC patients found that the 5-year overall survival was best for patients with HPV(+)/p16(+) tumors, intermediate for HPV(−)/p16(+) tumors, and worst for HPV(+)/p16(−) and HPV(−)/p16(−) tumors [37].